Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV
Contemporary Clinical Trials · 2026
DOI: 10.1016/j.cct.2025.108144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2026. Verfasst von Ana Gabriela Pires Dos Santos und 15 weiteren Autor:innen. Beteiligte Einrichtung: AbbVie Inc., North Chicago, IL, USA. Electronic address: Ana.pires@abbvie.com. Hauptthemen laut MEDLINE: HIV Infections, Withholding Treatment, Anti-HIV Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc.
Abstract (Originalsprache)
BACKGROUND: Immune-mediated interventions have the potential to induce long-term antiretroviral treatment (ART)-free viral suppression in people with HIV. However, in the absence of biomarkers of viral control, studies looking at immune interventions require a planned long-term analytical treatment interruption (ATI) that may bring risks to participants and challenges for data interpretation. Herein, we describe an ongoing, global, proof-of-concept, randomized, placebo-controlled, phase 2 clinical trial with a planned ATI and illustrate how those risks have been mitigated to safely evaluate the long-term durability of ART-free viral control. METHODS: The trial evaluates an immunologic combination of low-dose budigalimab and trosunilimab administered during ATI. Adults aged 18-70 with confirmed HIV-1 on stable ART with viremia below the limit of detection and CD4+ counts >500 cells/mL willing to undergo ATI are randomized to receive budigalimab, trosunilimab, both (at 2 different trosunilimab doses), or neither. The primary efficacy endpoint is the proportion of participants achieving viral control (HIV-1 RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AbbVie Inc., North Chicago, IL, USA. Electronic address: Ana.pires@abbvie.com.
- AbbVie Inc., North Chicago, IL, USA.
- Department of Infectious Diseases and IrsiCaixa, Hospital Germans Trias i Pujol Badalona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; University of Vic-Central Un…
- McGill University Health Centre, Montreal, QC, Canada.
- Quest Clinical Research, San Francisco, CA, USA.
- Prism Health North Texas, Dallas, TX, USA.
Förderung
- AbbVie Inc
Zitieren
APA
Pires Dos Santos, A. G., Abunimeh, M., Mothe, B., Routy, J. P., Lalezari, J. P., Sinclair, G. I., Sokhela, S. M., Diaz, R. S., Schwarze, S., Berry, J., Lewin, S. R., Dubé, K., Krishnan, P., Topp, A., Gill, S., & Cohen, D. (2026). Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2025.108144
Vancouver
Pires Dos Santos AG, Abunimeh M, Mothe B, Routy JP, Lalezari JP, Sinclair GI, et al. Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV. Contemporary Clinical Trials. 2026. doi:10.1016/j.cct.2025.108144
BibTeX
@article{PiresDosSantos2026,
author = {Pires Dos Santos, Ana Gabriela and Abunimeh, Manal and Mothe, Beatriz and Routy, Jean-Pierre and Lalezari, Jacob P and Sinclair, Gary I and Sokhela, Simiso M and Diaz, Ricardo Sobhie and Schwarze, Siegfried and Berry, Jeff and Lewin, Sharon R and Dubé, Karine and Krishnan, Preethi and Topp, Andrew and Gill, Sarah and Cohen, Daniel},
title = {Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV},
journal = {Contemporary Clinical Trials},
year = {2026},
doi = {10.1016/j.cct.2025.108144}
}
EUVIMED